NEW YORK, August 21, 2026, 5:17 p.m. EDT
- RFAI closed at $58.00, up 355.6% Friday and 524.3% for the week.
- Shareholders approved the Nanyang Biologics deal by 6,765,584 votes to 440,604.
- Preliminary redemption requests cover 3,956,323 shares; final trust cash and public float remain unknown.
RF Acquisition Corp II NASDAQ:RFAI jumped 355.6% on Friday after shareholders approved its proposed combination with Nanyang Biologics. The shares closed at $58.00 after trading between $35.22 and $73.00. Volume reached 2.85 million shares.
The vote cleared a major deal condition. Yet the more important number for investors may be 3,956,323. That is the preliminary count of shares submitted for redemption.
Those requests equal 98.95% of the 3,998,108 ordinary shares outstanding after an earlier August redemption. Requests can still be withdrawn or reversed with company consent. RF Acquisition said final trust cash and public float cannot be known until closing.
| Friday price action | Value | Comparison |
|---|---|---|
| Close | $58.00 | +$45.27 from Thursday |
| Daily change | +355.6% | From $12.73 |
| Regular-session range | $35.22–$73.00 | 107.3% low-to-high spread |
| Volume | 2.85 million | 10.3× Thursday’s 276,700 |
| After-hours | $48.00 | -17.2% from close at 5:17:38 p.m. EDT |
The business-combination proposal passed with 93.9% of votes cast in favor. The same tally approved the merger and Nasdaq share issuance. That support removes the ballot hurdle, but not the closing conditions.
| August 20 vote | For | Against | Abstain |
|---|---|---|---|
| Business combination | 6,765,584 | 440,604 | 0 |
| Merger | 6,765,584 | 440,604 | 0 |
| Nasdaq share issuance | 6,765,584 | 440,604 | 0 |
A preliminary scenario shows the cash tension. The trust held about $44.52 million after 833,157 shares were redeemed at roughly $11.13 each on August 12. Applying that same approximate rate to the new requests implies a $44.03 million payment and about $0.49 million left. This is an estimate, not the final outcome.
| Redemption bridge | Reported or estimated value | Status |
|---|---|---|
| Trust after August 12 redemptions | $44.52 million | Reported |
| Approximate prior redemption rate | $11.13 per share | Reported |
| New preliminary requests | 3,956,323 shares | Reported; reversible |
| Implied payment at $11.13 | $44.03 million | Preliminary estimate |
| Implied residual trust | $0.49 million | Preliminary estimate |
The proposed transaction assigns Nanyang about $1.5 billion of pre-transaction equity value. Existing Nanyang holders would roll over all their equity and retain a majority. The combined company expects to trade under NYB. RF Acquisition Chairman Tse Meng Ng said the transaction reflected confidence in Nanyang’s ability to create “lasting value for patients, shareholders, and the broader healthcare ecosystem.” Original deal announcement
Friday transformed a normally stable SPAC share. RFAI ended Monday at $9.29, then rose to $10.00, $11.19 and $12.73 before Friday’s surge. The close stood 421.1% above the earlier approximate redemption value.
| Week ended August 21 | Close | One-day move |
|---|---|---|
| Monday | $9.29 | — |
| Tuesday | $10.00 | +7.6% |
| Wednesday | $11.19 | +12.0% |
| Thursday | $12.73 | +13.7% |
| Friday | $58.00 | +355.6% |
Sell-side coverage offers little valuation support. MarketBeat lists one current recommendation, a Weiss Ratings Sell, and no published price target. No verified Buy or Hold recommendation appears in that dataset.
| Analyst recommendations | Count | Price target | Latest identified source |
|---|---|---|---|
| Buy | 0 | None published | MarketBeat compilation |
| Hold | 0 | None published | MarketBeat compilation |
| Sell | 1 | None published | Weiss Ratings |
| Consensus | 1 rating | Not available | Sell |
RF Acquisition remains a shell company until closing. At June 30 it held $10,191 of cash outside the trust and reported a $1.28 million working-capital deficit. Management also cited substantial doubt about its ability to continue as a going concern.
Nanyang’s operating case is separate from Friday’s float mechanics. Its Vecura platform combines artificial intelligence with a natural-compound library. The company says its platform screened 700,000 compounds in five months and has since expanded the library beyond 1.5 million compounds.
Next week, investors should watch the final redemption count, trust proceeds, closing timing and post-close float. A confirmed tiny float could keep volatility high. Withdrawn redemptions would change both liquidity and cash available to the combined company.
Risks: The combination may still fail to close. Redemptions, dilution, additional financing and a sharply smaller public float could produce large price gaps. Nanyang’s drug programs also carry clinical, regulatory and commercialization risk.
Related articles: Stock Market
